At a glance
ClinicalIndex Comparison Record- ✓Histologic diagnosis of prostate adenocarcinoma
- ✓High or very high-risk disease: cT3a-cT4, Grade group 4-5 (Gleason 8-10), or PSA >20 ng/mL
- ✓Documented germline pathogenic/likely pathogenic variant in BRCA1 or BRCA2 from CLIA-certified lab
- ✓Age ≥18 years
- ✕No evidence of distant metastatic disease by conventional imaging within 90 days (cN1 by PSMA-PET alone permitted if resectable)
- ✕No prior radiation therapy to the pelvic region
- ✕No prior or concurrent malignancy that could interfere with safety or efficacy assessment
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
S2210 A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer With Germline BRCA1/2 Mutations
In Brief
A Phase 2 clinical trial evaluating Biospecimen Collection, Carboplatin, and 5 other interventions for Prostate Adenocarcinoma and 2 related conditions. Currently recruiting, targeting 44 participants across 133 sites.
Signals
Detailed Summary
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells. Giving carboplatin before surgery may shrink tumors in patients with high-risk prostate cancer with BRCA1 and BRCA2 gene mutations.
Study Details
Timeline
Interventions
Undergo collection of blood samples
Given IV
Undergo chest X-ray
Undergo CT
Undergo MRI
Undergo PSMA PET
Undergo surgery